Role of Tetraspan Glycoproteins (CD63) in HIV Entry
四跨糖蛋白 (CD63) 在 HIV 进入中的作用
基本信息
- 批准号:6833509
- 负责人:
- 金额:$ 33.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-12-15 至 2006-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
EXCEEDTHE SPACE PROVIDED. HIV infection of primary human cells typically requires interaction with both the primary receptor CD4 and a chemokinecoreceptor either CCRS or CXCR4. We have discovered a potential role for CD63 in HIV infection of M0, as monoclonal antibodies (mAb specific for CD63 can prevent HIV entry into MO, but not T-cells. CD63 is a tetraspan membrane glycoprotein, best known as a1 activation marker on platelets, that is nearly ubiquitous on human cells and is closely associated with integrins. Our experimentswil investigate the role of CD63 in HIV entry into M0. These studies may lead to developmentof novel antiretroviraltherapies targetini HIV entry. We will pursue these Aims over five years: Specific Aim 1. To test the hypothesis that infection of M0by diverse primary HIV-1 strains can be inhibited by anti-CD63 mAb This will include both subtype B and non-subtypeB strains, includingsome that use CCRS as a coreceptor (R5), as well as dual-tropic strains that use either CXCR4 or CCRS (RSX4), and X4 strains able to replicate in M0. Amphotropic MLV-Env-pseudotyped virus which enters independent of CD4 and CCRYCXCR4 interactions, will be assessed to determine if anti-CD63 irhbition acts at post binding retroviral entry events. Specific Aim 2. To test the hypothesis that cell-specific differences between HIV target cells affect the role of CD63 in facilitatini HIV entry. We will control for and test effects of various levels of receptor/coreceptor/CD63 expression and activation markers 01 susceptibility to anti-CD63 inhibition. We will also test cell line models of anti-CD63 inhibition, which would facilitate cel manipulation and the consistencycif lnhibitoryeffects in these studies,and in the mechanistic studiesin Aim 3. Specific Aim 3. To test the hypothesis that CD63 has a specific role in facilitating HIV entry into macrophages, we will identify potential mechanisms of CD63-mediatedHIV entry, including (a) receptor/coreceptor interactions or colocalization with CD63, (b) CD63 binding to gp120, (c) the role of CD63 in CD4 turnover or virus/receptor endocytosis and (d) signal transduction. These experiments will be prioritized based on anti-CD63 susceptibility of MLV-Env pseudotyped virus (and X4 HIV-1 strains), which would direct us to focus on late events if inhibition is not dependent on CD4 and CCRS-associated events. Achieving these Aims will provide important new insights into the mechanism of HIV-1 entry, and may well provide important new targets for antiretroviraltherapy. PERFORMANCESITE( ========================================Section End===========================================
超过提供的空间。原代人细胞的HIV感染通常需要与原代受体CD4和趋化感受器受体CCR或CXCR4相互作用。 We have discovered a potential role for CD63 in HIV infection of M0, as monoclonal antibodies (mAb specific for CD63 can prevent HIV entry into MO, but not T-cells. CD63 is a tetraspan membrane glycoprotein, best known as a1 activation marker on platelets, that is nearly ubiquitous on human cells and is closely associated with integrins. Our experimentswil investigate the role of CD63进入M0。这些研究可能会导致新型抗逆转录病毒抗体的发育,我们将在五年内追求这些目标:特定目标1。共核能(R5)以及使用CXCR4或CCRS(RSX4)和能够在M0中复制的X4菌株的双重菌株事件。特定目的2。检验以下假设:HIV靶细胞之间的细胞特异性差异会影响CD63在促进HIV进入中的作用。我们将控制和测试各种受体/共感受器/CD63表达和激活标志物01对抗CD63抑制的敏感性。 We will also test cell line models of anti-CD63 inhibition, which would facilitate cel manipulation and the consistencycif lnhibitoryeffects in these studies,and in the mechanistic studiesin Aim 3. Specific Aim 3. To test the hypothesis that CD63 has a specific role in facilitating HIV entry into macrophages, we will identify potential mechanisms of CD63-mediatedHIV entry, including (a) receptor/coreceptor interactions or与CD63,(b)CD63与GP120,(c)CD63在CD4周转或病毒/受体内吞作用和(d)信号转导的作用。这些实验将基于MLV-ENV伪型病毒(和X4 HIV-1菌株)的抗CD63敏感性进行优先级,如果抑制不依赖于CD4和CCRS相关事件,该实验将指导我们专注于后期事件。实现这些目标将为HIV-1进入机制提供重要的新见解,并很可能为抗逆转录病毒疗法提供重要的新目标。表演场(===========================================================================================================
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A critical role for CD63 in HIV replication and infection of macrophages and cell lines.
- DOI:10.1016/j.virol.2008.06.029
- 发表时间:2008-09-30
- 期刊:
- 影响因子:3.7
- 作者:Chen, Hui;Dziuba, Natallia;Friedrich, Brian;von Lindern, Jana;Murray, James L.;Rojo, Daniel R.;Hodge, Thomas W.;O'Brien, William A.;Ferguson, Monique R.
- 通讯作者:Ferguson, Monique R.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WILLIAM AUSTIN O'BRIEN其他文献
WILLIAM AUSTIN O'BRIEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WILLIAM AUSTIN O'BRIEN', 18)}}的其他基金
FINITE ELEMENT SIMULATION OF SOUND WAVE PROPAGATION INTO THE HUMAN HEAD
声波传播到人脑的有限元模拟
- 批准号:
8171741 - 财政年份:2010
- 资助金额:
$ 33.53万 - 项目类别:
FINITE ELEMENT SIMULATION OF SOUND WAVE PROPAGATION INTO THE HUMAN HEAD
声波传播到人脑的有限元模拟
- 批准号:
7956291 - 财政年份:2009
- 资助金额:
$ 33.53万 - 项目类别:
Characterization of Cellular Proteins Involved in HIV Infection
HIV 感染相关细胞蛋白的表征
- 批准号:
7757981 - 财政年份:2009
- 资助金额:
$ 33.53万 - 项目类别:
ACTG 5178: SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS
ACTG 5178:丙型肝炎病毒的抑制性长期抗病毒治疗
- 批准号:
7605393 - 财政年份:2007
- 资助金额:
$ 33.53万 - 项目类别:
ACTG A5142: A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/
ACTG A5142:洛匹那韦/洛匹那韦的 III 期、随机、开放标签比较
- 批准号:
7378718 - 财政年份:2006
- 资助金额:
$ 33.53万 - 项目类别:
ACTG A5223: SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS AMONG
ACTG A5223:洛匹那韦/利托那韦药代动力学的性别差异
- 批准号:
7378744 - 财政年份:2006
- 资助金额:
$ 33.53万 - 项目类别:
ACTG 5178: SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS
ACTG 5178:丙型肝炎病毒的抑制性长期抗病毒治疗
- 批准号:
7378723 - 财政年份:2006
- 资助金额:
$ 33.53万 - 项目类别:
ACTG A5210: A PHASE IB/IIA DOSE-FINDING SAFETY AND ACTIVITY STUDY OF AMD 11070
ACTG A5210:AMD 11070 的 IB/IIA 期剂量探索安全性和活性研究
- 批准号:
7202595 - 财政年份:2005
- 资助金额:
$ 33.53万 - 项目类别:
Role of Tetraspan Glycoproteins (CD63) in HIV Entry
四跨糖蛋白 (CD63) 在 HIV 进入中的作用
- 批准号:
6590953 - 财政年份:2002
- 资助金额:
$ 33.53万 - 项目类别:
Role of Tetraspan Glycoproteins (CD63) in HIV Entry
四跨糖蛋白 (CD63) 在 HIV 进入中的作用
- 批准号:
6688454 - 财政年份:2002
- 资助金额:
$ 33.53万 - 项目类别:
相似国自然基金
线粒体靶向四面体框架核酸tFNAs在脊髓损伤神经修复中的作用与机制研究
- 批准号:82302884
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
功能化四面体框架核酸/Ac-PGP复合纳米材料靶向调控NETs治疗牙周炎的研究
- 批准号:82301146
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于核酸四面体“信号增强塔”的微针分子识别系统在炎症因子风暴多层面实时监测中的研究和应用
- 批准号:22374029
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
四面体框架核酸空间介导有机磷农药免疫层析增敏机理研究
- 批准号:32302207
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
四面体框架核酸定域矿化水凝胶支架促进牙周组织再生研究
- 批准号:52373145
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Role of Tetraspan Glycoproteins (CD63) in HIV Replication
四跨糖蛋白 (CD63) 在 HIV 复制中的作用
- 批准号:
7867157 - 财政年份:2009
- 资助金额:
$ 33.53万 - 项目类别:
Role of Tetraspan Glycoproteins (CD63) in HIV Entry
四跨糖蛋白 (CD63) 在 HIV 进入中的作用
- 批准号:
6590953 - 财政年份:2002
- 资助金额:
$ 33.53万 - 项目类别:
Role of Tetraspan Glycoproteins (CD63) in HIV Entry
四跨糖蛋白 (CD63) 在 HIV 进入中的作用
- 批准号:
6688454 - 财政年份:2002
- 资助金额:
$ 33.53万 - 项目类别:
Role of Tetraspan Glycoproteins (CD63) in HIV Replication
四跨糖蛋白 (CD63) 在 HIV 复制中的作用
- 批准号:
8098853 - 财政年份:2002
- 资助金额:
$ 33.53万 - 项目类别:
Role of Tetraspan Glycoproteins (CD63) in HIV Replication
四跨糖蛋白 (CD63) 在 HIV 复制中的作用
- 批准号:
7289785 - 财政年份:2002
- 资助金额:
$ 33.53万 - 项目类别: